Does orphan drug legislation really answer the needs of patients?
Lancet
.
2008 Jun 14;371(9629):2041-4.
doi: 10.1016/S0140-6736(08)60873-9.
Authors
Marlene E Haffner
1
,
Josep Torrent-Farnell
,
Paul D Maher
Affiliation
1
Office of Orphan Products Development, Food and Drug Administration, Amgen, Washington, DC, USA.
PMID:
18555916
DOI:
10.1016/S0140-6736(08)60873-9
No abstract available
MeSH terms
European Union
Health Services Needs and Demand*
Humans
Motivation
Orphan Drug Production / economics
Orphan Drug Production / legislation & jurisprudence*
Rare Diseases / drug therapy*
United States